Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 261K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Eckenberg, R. Articles by Thèze, J. Search for Related Content PubMed PubMed Citation Articles by Eckenberg, R. Articles by Thèze, J. Social Bookmarking                            What's this?

Original Article

The First Helix of Interleukin (Il)-2 Folds as a Homotetramer, Acts as an Agonist of the IL-2 Receptor β Chain, and Induces Lymphokine-Activated Killer Cells

^a From the Unité d'Immunogénétique Cellulaire, Institut Pasteur, 75015 Paris, France
^b From the Unité de Biochimie Cellulaire, Institut Pasteur, 75015 Paris, France
^c From the Unité de Biologie Moléculaire Expression Génique, Institut Pasteur, 75015 Paris, France
^d From the Unité de Biochimie Structurale, Institut Pasteur, 75015 Paris, France
^e Institut National de la Santé et de la Recherche Médicale (INSERM), U461, 92296 Chatenay-Malabry, France
^f INSERM, U463, 44000 Nantes, France
^g Chimie des Biomolécules, Institut Pasteur, 59000 Lille, France
^h INSERM, U487, 94805 Villejuif, France
Unité d'Immunogénétique Cellulaire, Département d'Immunologie, Institut Pasteur, 25 & 28 rue du Dr. Roux, 75724 Paris cedex 15, France.33-1-45-68-88-3833-1-45-68-86-28/86-00

jtheze{at}pasteur.fr

Interleukin (IL)-2 interacts with two types of functional receptors (IL-2Rβ and IL-2Rβ) and acts on a broad range of target cells involved in inflammatory reactions and immune responses. For the first time, we show that a chemically synthesized fragment of the IL-2 sequence can fold into a molecule mimicking the quaternary structure of a hemopoietin. Indeed, peptide p1–30 (containing amino acids 1–30, covering the entire helix A of IL-2) spontaneously folds into an -helical homotetramer and stimulates the growth of T cell lines expressing human IL-2Rβ, whereas shorter versions of the peptide lack helical structure and are inactive. We also demonstrate that this neocytokine interacts with a previously undescribed dimeric form of IL-2Rβ. In agreement with its binding to IL-2Rβ, p1–30 activates Shc and p56^lck but unlike IL-2, fails to activate Janus kinase (Jak)1, Jak3, and signal transducer and activator of transcription 5 (STAT5). Unexpectedly, we also show that p1–30 activates Tyk2, thus suggesting that IL-2Rβ may bind to different Jaks depending on its oligomerization. At the cellular level, p1–30 induces lymphokine-activated killer (LAK) cells and preferentially activates CD8^low lymphocytes and natural killer cells, which constitutively express IL-2Rβ. A significant interferon production is also detected after p1–30 stimulation. A mutant form of p1–30 (Asp20Lys), which is likely unable to induce vascular leak syndrome, remains capable of generating LAK cells, like the original p1–30 peptide. Altogether, our data suggest that p1–30 has therapeutic potential.

Key Words: interleukin 2 mimetic • synthetic hemopoietin • dimeric interleukin 2 receptor • β chain • signal transduction • natural killer cells

Abbreviations used in this paper: A domain, acidic domain; aa, amino acid; CD, circular dichroism; EMSA, electrophoretic mobility shift assay; EPO, erythropoietin; FLC, fluorescein; GAS, IFN-–activated sequence; Jak, Janus kinase; K_d, dissociation constant; LAK, lymphokine-activated killer cell; PTK, protein tyrosine kinase; S domain, serine-rich domain; STAT, signal transducer and activator of transcription; VLS, vascular leak syndrome.

© 2000 The Rockefeller University Press

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS